Tinkering Around Healthcare Infrastructures: Nursing Practices and Junction Work

Enrico Maria Piras,A. Zanutto

DOI: https://doi.org/10.1007/978-3-319-33464-6_11

Abstract:

What problem does this paper attempt to address?

Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis

Alexander Hapfelmeier,Begum Irmak On,Mark Mühlau,Jan S Kirschke,Achim Berthele,Christiane Gasperi,Ulrich Mansmann,Alexander Wuschek,Matthias Bussas,Martin Boeker,Antonios Bayas,Makbule Senel,Joachim Havla,Markus C Kowarik,Klaus Kuhn,Ingrid Gatz,Helmut Spengler,Benedikt Wiestler,Lioba Grundl,Dominik Sepp,Bernhard Hemmer

DOI: https://doi.org/10.1177/17562864231161892

2023-03-24

Abstract:Background: Multiple sclerosis (MS) is a chronic neuroinflammatory disease affecting about 2.8 million people worldwide. Disease course after the most common diagnoses of relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) is highly variable and cannot be reliably predicted. This impairs early personalized treatment decisions. Objectives: The main objective of this study was to algorithmically support clinical decision-making regarding the options of early platform medication or no immediate treatment of patients with early RRMS and CIS. Design: Retrospective monocentric cohort study within the Data Integration for Future Medicine (DIFUTURE) Consortium. Methods: Multiple data sources of routine clinical, imaging and laboratory data derived from a large and deeply characterized cohort of patients with MS were integrated to conduct a retrospective study to create and internally validate a treatment decision score [Multiple Sclerosis Treatment Decision Score (MS-TDS)] through model-based random forests (RFs). The MS-TDS predicts the probability of no new or enlarging lesions in cerebral magnetic resonance images (cMRIs) between 6 and 24 months after the first cMRI. Results: Data from 65 predictors collected for 475 patients between 2008 and 2017 were included. No medication and platform medication were administered to 277 (58.3%) and 198 (41.7%) patients. The MS-TDS predicted individual outcomes with a cross-validated area under the receiver operating characteristics curve (AUROC) of 0.624. The respective RF prediction model provides patient-specific MS-TDS and probabilities of treatment success. The latter may increase by 5-20% for half of the patients if the treatment considered superior by the MS-TDS is used. Conclusion: Routine clinical data from multiple sources can be successfully integrated to build prediction models to support treatment decision-making. In this study, the resulting MS-TDS estimates individualized treatment success probabilities that can identify patients who benefit from early platform medication. External validation of the MS-TDS is required, and a prospective study is currently being conducted. In addition, the clinical relevance of the MS-TDS needs to be established.
A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views

Tjalf Ziemssen,Chloe Tolley,Bryan Bennett,Sarah Kilgariff,Eddie Jones,James Pike,Davorka Tomic,Daniela Piani-Meier,Raquel Lahoz

DOI: https://doi.org/10.1016/j.msard.2019.101861

Abstract:Objectives: The transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) evolves over time and it can be challenging for physicians to identify progression early. Typically, SPMS is diagnosed retrospectively with a significant delay, based on a history of gradual worsening, independent of relapses, following an initial relapsing-remitting disease course. As such, SPMS is often associated with a considerable period of diagnostic uncertainty. This study aimed to explore and characterize key symptoms and impacts associated with transitioning from RRMS to SPMS and inform the content for a tool to support evaluation of early subtle signs suggestive of progressive disease. Methods: The qualitative study involved 60-min, face-to-face, concept elicitation (CE) interviews with 32 patients with MS (US = 16 and Germany = 16); and 30-min, telephone, CE interviews with 16 neurologists (US = 8 and Germany = 8). Multivariate analysis on data from a real-world observational study of 3294 MS patients assessed the differences between early-RRMS and early-SPMS, and identified factors that were significant drivers of this difference. These studies informed selection of the key variables to be included in a pilot tool. Sixteen physicians used the pilot tool, presented as a paper questionnaire, with a sample of patients whom they suspected were progressing to SPMS (n ≥ 5). Following this, the physicians participated in a 30-min cognitive debriefing (CD) interview to evaluate the relevance and usefulness of the tool. Qualitative analysis of all anonymized, verbatim transcripts was performed using thematic analysis. Results: Patients and physicians reported signs that indicated progression to SPMS including gradual worsening of symptoms, lack of clear recovery, increased severity and presence of new symptoms. No specific symptoms definitively indicated progression to SPMS, however a number of potential symptoms associated with progression were identified by SPMS patients and physicians, including worsening ambulation, cognition, balance, muscle weakness, visual symptoms, bladder symptoms and fatigue. Quality of life domains reported to be more severely impacted in SPMS than MS in general included: physical activity, work, daily activities, emotional and social functioning. Multivariate analysis of the observational study data identified several variables strongly associated with progression to SPMS including, requirement of assistance in daily living, presence of motor symptoms, presence of ataxia/coordination symptoms, and unemployment. Physicians reported that items included in the tool were easy to understand and relevant. Physicians also reported that there is an unmet need for a tool to help identify signs of SPMS progression and so the tool would be useful in clinical practice. Conclusions: This was the first stage of development of a novel, validated, physician-completed tool to support physician-patient interactions in evaluating signs indicative of disease progression to SPMS. Qualitative and quantitative methods (involving physician and patients) were used to determine tool content. The usefulness and unmet need for such a tool in clinical practice was confirmed via CD interviews with physicians. Further work is now warranted to develop a scoring algorithm and validate the tool so that it can be reliably implemented in clinical practice.
Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score

Giulia Mallucci,Ottavia Eleonora Ferraro,Maria Trojano,Maria Pia Amato,Antonio Scalfari,Mauro Zaffaroni,Elena Colombo,Eleonora Rigoni,Pietro Iaffaldano,Emilio Portaccio,Lorenzo Saraceno,Damiano Paolicelli,Lorenzo Razzolini,Cristina Montomoli,Roberto Bergamaschi

DOI: https://doi.org/10.1007/s00415-024-12304-5

2024-03-26

Journal of Neurology

Abstract:BackgroundPredicting disease progression in patients with the first clinical episode suggestive of multiple sclerosis (MS) is crucial for personalized therapeutic approaches. This study aimed to develop the EUMUS score for accurately estimating the risk of early evidence of disease activity and progression (EDA).MethodsRetrospective analysis was conducted on data from 221 patients with a first clinical MS episode collected from four Italian MS centers. Various variables including socio-demographics, clinical features, cerebrospinal fluid analysis, evoked potentials, and brain MRI were considered. A prognostic multivariate regression model was identified to develop the EUMUS score. The optimal cutoff for predicting the transition from no evidence of disease activity (NEDA3) to EDA was determined. The accuracy of the prognostic model and score were tested in a separate UK MS cohort.ResultsAfter 12 months, 61.54% of patients experienced relapses and/or new MRI lesions. Younger age (OR 0.96, CI 0.93–0.99; p = 0.005), MRI infratentorial lesion(s) at baseline (OR 2.21, CI 1.27–3.87; p = 0.005), positive oligoclonal bands (OR 2.89, CI 1.47–5.69; p = 0.002), and abnormal lower limb somatosensory-evoked potentials (OR 2.77, CI 1.41–5.42; p = 0.003) were significantly associated with increased risk of EDA. The EUMUS score demonstrated good specificity (72%) and correctly classified 80% of patients with EDA in the independent UK cohort.ConclusionsThe EUMUS score is a simple and useful tool for predicting MS evolution within 12 months of the first clinical episode. It has the potential to guide personalized therapeutic approaches and aid in clinical decision-making.

clinical neurology
Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Jeffrey R. Curtis,Cecilie H. Brahe,Mikkel Østergaard,Merete Lund Hetland,Karen Hambardzumyan,Saedis Saevarsdottir,Xingbin Wang,Darl D. Flake,Eric H. Sasso,T. W. Huizinga,Darl D. Flake II

DOI: https://doi.org/10.1080/03007995.2019.1585064

2019-03-14

Current Medical Research and Opinion

Abstract:Objective: To compare the multi-biomarker disease activity (MBDA) score with the DAS28-CRP and CRP for predicting risk of radiographic progression in patients with rheumatoid arthritis.Methods: Published studies of the MBDA score and radiographic progression with ≥100 patients per cohort were evaluated. Rates of radiographic progression over 1 year were determined across the low/moderate/high categories for MBDA score (low/moderate/high: <30, 30-44, >44), DAS28-CRP (low/moderate/high: ≤2.67, >2.67-4.09, >4.09) and CRP (low/moderate/high: ≤10, >10-30, >30 mg/L), with positive and negative predictive value (PPV, NPV) and relative risk (RR) determined for high vs. not-high (i.e. low and moderate combined) categories. Patient-level data from studies having all three measures was pooled to: (1) determine a combined RR for radiographic progression in the high vs. not-high categories for each measure; and (2) compare the predictive ability of MBDA score vs. DAS28-CRP by comparing the rates of radiographic progression observed in subgroups created by cross-classifying the high and not-high categories of each measure.Results: Five cohorts were identified for inclusion (total N=929). In each, radiographic progression was more frequent with increasing MBDA scores. Among the three cohorts with requisite data, PPVs were generally similar using categories of MBDA score, DAS28-CRP or CRP but NPVs were greater for MBDA score (93-97%) than DAS28-CRP or CRP (77-87%). RRs for radiographic progression were greater when based on categories of MBDA score than DAS28-CRP or CRP and the combined RR was greater for MBDA score (4.6, p < .0001) than DAS28-CRP (1.7, p = .02) or CRP (1.7, p = .002). For patients cross-classified by MBDA score and DAS28-CRP, high vs. not-high MBDA score significantly predicted radiographic progression independently of DAS28-CRP.Conclusions: High and not-high MBDA scores were associated with increased and low risk, respectively, for radiographic progression over one year. MBDA score was a better predictor of radiographic progression than DAS28-CRP or CRP.

medicine, general & internal, research & experimental
Accuracy of MSBase Criteria to Diagnose Secondary Progressive Multiple Sclerosis in Large German Real-World Patient Cohort

Braune Stefan,Karamasioti Eleni,van Hoevell Philip,Bergmann Arnfin,Skuljec Jelena,Siva Aksel,NTD Study Group,Pul Refik

DOI: https://doi.org/10.1016/j.msard.2024.105844

IF: 4.808

2024-08-26

Multiple Sclerosis and Related Disorders

Abstract:Background and Objectives Accurate diagnosis of secondary progression in multiple sclerosis (MS) remains a challenge since standardized criteria are missing. In 2016, the MSBase registry presented an algorithm that enabled the diagnosis of secondary progressive multiple sclerosis (SPMS) more than three years earlier compared to diagnosis by neurologists. This work aimed to test whether this approach is equally effective in a real-world cohort of MS patients. Methods This longitudinal retrospective study analyzed clinical data of outpatients with MS recorded until October 2020 in the NeuroTransData registry, a Germany-wide network of 153 certified neurologists. Patient data had been captured in time during clinical visits employing a defined standardized clinical data set in the webbased NeuroTransData patient management platform DESTINY®. The time between the diagnosis of relapsing-remitting multiple sclerosis (RRMS) to SPMS onset was compared with one determined using MSBase criteria (MSBC). Group 1 consisted of patients diagnosed with SPMS during the observation period, whereas group 2 included RRMS patients who did not convert to SPMS during the observation period. Results Of 21,281 patients with MS included in our registry, 194 and 9506 patients were allocated to groups 1 and 2, respectively. 10.3% of patients with RRMS were diagnosed with SPMS simultaneously, whereas 60.8% were diagnosed with SPMS at least 3 months earlier by treating neurologists compared to the MSBC. In group 1, the MSBC showed a low sensitivity of 32.0% and an accuracy of 61.4% but a high specificity of 89.6%. In group 2, the MSBC identified 7.8% of patients with SPMS at some point during the observation time. Moreover, test-retest variability remains a challenge since 29.4% of patients diagnosed with SPMS by treating physicians did not fulfil the MSBC at a later point in time. Discussion These results are inconsistent with earlier SPMS diagnosis using the MSBC compared to clinical diagnosis by treating physicians. Therefore, there remains a need for an operational, structured, and validated approach to SPMS diagnosis.

clinical neurology
Validation of a Set of Clinical Criteria for the Diagnosis of Secondary Progressive Multiple Sclerosis

Alin Ciubotaru,Daniel Alexa,Cristina Grosu,Lilia Böckels,Ioana Păvăleanu,Alexandra Maștaleru,Maria Magdalena Leon,Roxana Covali,Emanuel Matei Roman,Cătălina Elena Bistriceanu,Cristina Mihaela Ghiciuc,Doina Azoicăi,Emilian Bogdan Ignat

DOI: https://doi.org/10.3390/brainsci14111141

IF: 3.333

2024-11-20

Brain Sciences

Abstract:Background/Objectives: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by progressive impairment of neuronal transmission due to focal demyelination. The most common form is RRMS (relapsing-remitting multiple sclerosis), which, under the influence of certain factors, can progress to SPMS (secondary progressive multiple sclerosis). Our study aimed to validate the criteria proposed by a working group of the Romanian Society of Neurology versus the criteria proposed by a group of experts from Spain, Karolinska, and Croatia concerning the progression from RRMS to SPMS. Methods: This was done by gathering epidemiological data (age, gender) and by applying clinical tests such as the 9HPT (9-hole peg test), 25FWT (25-foot walk test), and EDSS (expanded disability status scale) tests and the SDMT test (symbol digit modalities test). The present research is a cohort study that included a number of 120 patients diagnosed with MS according to the McDonald Diagnostic Criteria 2017. The study was carried out between January 2023 and April 2024, including patients hospitalized in the Neurology Clinic of the Clinical Rehabilitation Hospital from Iasi, Romania. The data were collected at baseline (T0) and at a 12-month interval (T1). Results: The statistical analysis was conducted using Kaiser–Meyer–Olkin analysis, which indicated a value of 0.683, thus validating the clinical tests used. The correlation matrix and the linear regression for all the tests showed highly significant statistical results. Furthermore, the ROC curve analysis of the criteria suggested by the working group of the Romanian Society of Neurology demonstrated that the EDSS, 9HPT, and 25FWT are highly sensitive in diagnosing SPMS, an opinion that is shared with the Spanish experts, but not with the Karolinska expert panel. Using the criteria given by the Croatian expert group in the ROC curve analysis showed that only the EDSS was strongly significant for the progression to the SPMS phase. Conclusions: In conclusion, all clinical methods used demonstrated that they are valid and can contribute to identifying patients with an increased risk of progression. The model proposed by the Romanian Society of Neurology working group is similar to other countries' expert opinions and can be used to detect the risk of disease progression and establish a more tailored therapeutic management of SPMS.

neurosciences
Development and validation of a clinical prediction tool to estimate survival in community-dwelling adults living with dementia: a protocol

Bonares,M.,Fisher,S.,Clarke,A.,Dover,K.,Quinn,K.,Stall,N.,Isenberg,S.,Tanuseputro,P.,Li,W.

DOI: https://doi.org/10.1136/bmjopen-2024-086231

IF: 3.006

2024-11-23

BMJ Open

Abstract:Introduction A clinical prediction tool to estimate life expectancy in community-dwelling individuals living with dementia could inform healthcare decision-making and prompt future planning. An existing Ontario-based tool for community-dwelling elderly individuals does not perform well in people living with dementia specifically. This study seeks to develop and validate a clinical prediction tool to estimate survival in community-dwelling individuals living with dementia receiving home care in Ontario, Canada. Methods and analysis This will be a population-level retrospective cohort study that will use data in linked healthcare administrative databases at ICES. Specifically, data that are routinely collected from regularly administered assessments for home care will be used. Community-dwelling individuals living with dementia receiving home care at any point between April 2010 and March 2020 will be included (N200 000). The model will be developed in the derivation cohort (N140 000), which includes individuals with a randomly selected home care assessment between 2010 and 2017. The outcome variable will be survival time from index assessment. The selection of predictor variables will be fully prespecified and literature/expert-informed. The model will be estimated using a Cox proportional hazards model. The model's performance will be assessed in a temporally distinct validation cohort (N60 000), which includes individuals with an assessment between 2018 and 2020. Overall performance will be assessed using Nagelkerke's R 2 , discrimination using the concordance statistic and calibration using the calibration curve. Overfitting will be assessed visually and statistically. Model performance will be assessed in the validation cohort and in prespecified subgroups. Ethics and dissemination The study received research ethics board approval from the Sunnybrook Health Sciences Centre (SUN-6138). s of the project will be submitted to academic conferences, and a manuscript thereof will be submitted to a peer-reviewed journal for publication. The model will be disseminated on a publicly accessible website (www.projectbiglife.com). Trial registration number NCT06266325 (clinicaltrials.gov).

medicine, general & internal
Accurate classification of secondary progression in multiple sclerosis

Ryan Ramanujam,Feng Zhu,Katharina Fink,Virginija Danylaitė Karrenbauer,Johannes Lorscheider,Pascal Benkert,Elaine Kingwell,Helen Tremlett,Jan Hillert,Ali Manouchehrinia

DOI: https://doi.org/10.1101/2020.07.09.20149674

2020-01-01

Abstract:AbstractTransition from a relapsing-remitting to the secondary progressive phenotype is an important milestone in the clinical evolution of multiple sclerosis. In the absence of reliable imaging or biological markers of phenotype transition, assignment of current phenotype status relies on retrospective evaluation of the medical history of an individual. Here, we sought to determine if demographic and clinical information from multiple sclerosis patients can be used to accurately assign current disease phenotypes: either relapsing-remitting or secondary progressive status. Data from the most recent clinical visit of 14,387 multiple sclerosis patients were extracted from the Swedish Multiple Sclerosis Registry. Decision trees based on sex, symptom onset age, Expanded Disability Scale Status score, and age & disease duration at the most recent clinic visit, were examined to build a classifier to determine disease phenotype. Validation was conducted using an independent cohort of multiple sclerosis patients from British Columbia, Canada, and a previously published classifier to assign phenotype was also tested. Clinical records of 100 randomly selected patients were used to manually categorize phenotype by three independent neurologists. A decision tree (the classifier) containing only most recently available disability score and age obtained 89.3% (95% confidence intervals (CI): 88.8% to 89.8%) classification accuracy, defined as concordance with the latest reported status in the registry. Replication in an independent cohort from British Columbia resulted in 82.0% (95%CI: 81.0% to 83.1%) accuracy. A previously published classification algorithm with slight modifications achieved 77.8% (95%CI: 77.1% to 78.4%) accuracy when assigning disease phenotype. With complete patient history data, three neurologists obtained 84.7% accuracy on average compared with 85 for the classifier using the same data. The model is easily interpretable and could allow research studies and randomized clinical trials to estimate the probability of patients having already reached the secondary progressive stage when they have not yet been retrospectively assigned this status, and to standardize definitions of disease phenotype across different cohorts. Clinically, this model could assist neurologists by providing additional information about the probability of having secondary progressive disease. This could also benefit patients who may be introduced to new therapies targeting progressive multiple sclerosis.
Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort

Nikolaos Koutsouleris,Michelle Worthington,Lana Kambeitz-Ilankovic,Rachele Sanfelici,Paolo Fusar-Poli,Marlene Rosen,Stephan Ruhrmann,Alan Anticevic,Jean Addington,Thomas McGlashan,Larry Seidman,Ming Tsuang,Peter Falkai,Rebekka Lencer,Alessandro Bertolino,Joseph Kambeitz,Frauke Schultze-Lutter,Eva Meisenzahl,Jarmo Hietala,Paolo Brambilla,Rachel Upthegrove,Stefan Borgwardt,Stephen Wood,Philip McGuire,Dominic B. Dwyer,Diana O. Perkins,Carrie E. Bearden,Barbara A. Cornblatt,Kristin S. Cadenhead,Daniel H. Mathalon,Elaine F. Walker,Scott W. Woods,Raimo K.R. Salokangas,Raquel E. Gur,Tyrone D. Cannon

DOI: https://doi.org/10.1016/j.biopsych.2021.06.023

IF: 12.81

2021-11-01

Biological Psychiatry

Abstract:BackgroundTransition to psychosis is among the most adverse outcomes of the clinical high-risk (CHR) syndromes encompassing ultra-high-risk (UHR) and basic symptoms states. Clinical risk calculators may facilitate an early and individualized interception of psychosis, but their real-world implementation requires thorough validation across diverse risk populations, including young patients with depressive syndromes.MethodsWe validated the previously described NAPLS-2 calculator in 334 patients (26 with psychosis transition) with CHR or recent-onset depression (ROD) drawn from the multisite European PRONIA study. Patients were categorized into three risk enrichment levels, ranging from UHR, over CHR, to a broad risk population comprising CHR or ROD patients (CHR|ROD). We assessed how risk enrichment and different predictive algorithms influenced prognostic performance using reciprocal external validation.ResultsAfter calibration, the NAPLS-2 model predicted psychosis with a balanced accuracy [BAC(sensitivity,specificity)] of 68%(73%,63%) in the PRONIA-UHR, 67%(74%,60%) in CHR, and 70%(73%,66%) in CHR|ROD patients. Multiple model derivation in PRONIA-CHR|ROD and validation in NAPLS-2-UHR patients confirmed that broader risk definitions produced more accurate risk calculators [CHR|ROD-based vs. UHR-based performance: 67%(68%,66%) vs. 58%(61%,56%)]. Support-vector machines (SVM) were superior in CHR|ROD (BAC=71%), while ridge logistic regression and SVM performed similarly in CHR (BAC=67%) and UHR cohorts (BAC=65%). Attenuated psychotic symptoms predicted psychosis across risk levels, while younger age and reduced processing speed became increasingly relevant for broader risk cohorts.ConclusionsClinical-neurocognitive machine-learning models operating in young patients with affective and CHR syndromes facilitate a more precise and generalizable prediction of psychosis. Future studies should investigate their therapeutic utility in large-scale clinical trials.

neurosciences,psychiatry
Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

Jeffrey R Curtis,Michael E Weinblatt,Nancy A Shadick,Cecilie H Brahe,Mikkel Østergaard,Merete Lund Hetland,Saedis Saevarsdottir,Megan Horton,Brent Mabey,Darl D Flake 2nd,Rotem Ben-Shachar,Eric H Sasso,T W Huizinga

DOI: https://doi.org/10.1186/s13075-020-02389-4

2021-01-04

Abstract:Background: The multi-biomarker disease activity (MBDA) test measures 12 serum protein biomarkers to quantify disease activity in RA patients. A newer version of the MBDA score, adjusted for age, sex, and adiposity, has been validated in two cohorts (OPERA and BRASS) for predicting risk for radiographic progression. We now extend these findings with additional cohorts to further validate the adjusted MBDA score as a predictor of radiographic progression risk and compare its performance with that of other risk factors. Methods: Four cohorts were analyzed: the BRASS and Leiden registries and the OPERA and SWEFOT studies (total N = 953). Treatments included conventional DMARDs and anti-TNFs. Associations of radiographic progression (ΔTSS) per year with the adjusted MBDA score, seropositivity, and clinical measures were evaluated using linear and logistic regression. The adjusted MBDA score was (1) validated in Leiden and SWEFOT, (2) compared with other measures in all four cohorts, and (3) used to generate curves for predicting risk of radiographic progression. Results: Univariable and bivariable analyses validated the adjusted MBDA score and found it to be the strongest, independent predicator of radiographic progression (ΔTSS > 5) compared with seropositivity (rheumatoid factor and/or anti-CCP), baseline TSS, DAS28-CRP, CRP SJC, or CDAI. Neither DAS28-CRP, CDAI, SJC, nor CRP added significant information to the adjusted MBDA score as a predictor, and the frequency of radiographic progression agreed with the adjusted MBDA score when it was discordant with these measures. The rate of progression (ΔTSS > 5) increased from < 2% in the low (1-29) adjusted MBDA category to 16% in the high (45-100) category. A modeled risk curve indicated that risk increased continuously, exceeding 40% for the highest adjusted MBDA scores. Conclusion: The adjusted MBDA score was validated as an RA disease activity measure that is prognostic for radiographic progression. The adjusted MBDA score was a stronger predictor of radiographic progression than conventional risk factors, including seropositivity, and its prognostic ability was not significantly improved by the addition of DAS28-CRP, CRP, SJC, or CDAI.
Recurrent prostate cancer despite undetectable prostate specific antigen.

T. Takayama,J. Krieger,L. True,P. Lange

DOI: https://doi.org/10.1016/S0022-5347(17)36963-X

1992-11-01

Abstract:
Identifying individuals at high risk for dementia in primary care: Development and validation of the DemRisk risk prediction model using routinely collected patient data

David Reeves,Catharine Morgan,Daniel Stamate,Elizabeth Ford,Darren M. Ashcroft,Evangelos Kontopantelis,Harm Van Marwijk,Brian McMillan

DOI: https://doi.org/10.1371/journal.pone.0310712

IF: 3.7

2024-10-05

PLoS ONE

Abstract:Health policy in the UK and globally regarding dementia, emphasises prevention and risk reduction. These goals could be facilitated by automated assessment of dementia risk in primary care using routinely collected patient data. However, existing applicable tools are weak at identifying patients at high risk for dementia. We set out to develop improved risk prediction models deployable in primary care. Electronic health records (EHRs) for patients aged 60–89 from 393 English general practices were extracted from the Clinical Practice Research Datalink (CPRD) GOLD database. 235 and 158 practices respectively were randomly assigned to development and validation cohorts. Separate dementia risk models were developed for patients aged 60–79 (development cohort n = 616,366; validation cohort n = 419,126) and 80–89 (n = 175,131 and n = 118,717). The outcome was incident dementia within 5 years and more than 60 evidence-based risk factors were evaluated. Risk models were developed and validated using multivariable Cox regression. The age 60–79 development cohort included 10,841 incident cases of dementia (6.3 per 1,000 person-years) and the age 80–89 development cohort included 15,994 (40.2 per 1,000 person-years). Discrimination and calibration for the resulting age 60–79 model were good (Harrell's C 0.78 (95% CI: 0.78 to 0.79); Royston's D 1.74 (1.70 to 1.78); calibration slope 0.98 (0.96 to 1.01)), with 37% of patients in the top 1% of risk scores receiving a dementia diagnosis within 5 years. Fit statistics were lower for the age 80–89 model but dementia incidence was higher and 79% of those in the top 1% of risk scores subsequently developed dementia. Our models can identify individuals at higher risk of dementia using routinely collected information from their primary care record, and outperform an existing EHR-based tool. Discriminative ability was greatest for those aged 60–79, but the model for those aged 80–89 may also be clinical useful.

multidisciplinary sciences
Development and validation of a dementia risk score in the UK Biobank and Whitehall II cohorts

Melis Anatürk,Raihaan Patel,Klaus P Ebmeier,Georgios Georgiopoulos,Danielle Newby,Anya Topiwala,Ann-Marie G de Lange,James H Cole,Michelle G Jansen,Archana Singh-Manoux,Mika Kivimäki,Sana Suri

DOI: https://doi.org/10.1136/bmjment-2023-300719

Abstract:Background: Current dementia risk scores have had limited success in consistently identifying at-risk individuals across different ages and geographical locations. Objective: We aimed to develop and validate a novel dementia risk score for a midlife UK population, using two cohorts: the UK Biobank, and UK Whitehall II study. Methods: We divided the UK Biobank cohort into a training (n=176 611, 80%) and test sample (n=44 151, 20%) and used the Whitehall II cohort (n=2934) for external validation. We used the Cox LASSO regression to select the strongest predictors of incident dementia from 28 candidate predictors and then developed the risk score using competing risk regression. Findings: Our risk score, termed the UK Biobank Dementia Risk Score (UKBDRS), consisted of age, education, parental history of dementia, material deprivation, a history of diabetes, stroke, depression, hypertension, high cholesterol, household occupancy, and sex. The score had a strong discrimination accuracy in the UK Biobank test sample (area under the curve (AUC) 0.8, 95% CI 0.78 to 0.82) and in the Whitehall cohort (AUC 0.77, 95% CI 0.72 to 0.81). The UKBDRS also significantly outperformed three other widely used dementia risk scores originally developed in cohorts in Australia (the Australian National University Alzheimer's Disease Risk Index), Finland (the Cardiovascular Risk Factors, Ageing, and Dementia score), and the UK (Dementia Risk Score). Clinical implications: Our risk score represents an easy-to-use tool to identify individuals at risk for dementia in the UK. Further research is required to determine the validity of this score in other populations.
Predicting patients with dementia most at risk of needing psychiatric in-patient or enhanced community care using routinely collected clinical data: retrospective multi-site cohort study

Sabina R. London,Shanquan Chen,Emad Sidhom,Jonathan R. Lewis,Emma Wolverson,Rudolf N. Cardinal,David Roalf,Christoph Mueller,Benjamin R. Underwood

DOI: https://doi.org/10.1192/bjp.2024.14

2024-05-15

The British Journal of Psychiatry

Abstract:Background Dementia is a common and progressive condition whose prevalence is growing worldwide. It is challenging for healthcare systems to provide continuity in clinical services for all patients from diagnosis to death. Aims To test whether individuals who are most likely to need enhanced care later in the disease course can be identified at the point of diagnosis, thus allowing the targeted intervention. Method We used clinical information collected routinely in de-identified electronic patient records from two UK National Health Service (NHS) trusts to identify at diagnosis which individuals were at increased risk of needing enhanced care (psychiatric in-patient or intensive (crisis) community care). Results We examined the records of a total of 25 326 patients with dementia. A minority (16% in the Cambridgeshire trust and 2.4% in the London trust) needed enhanced care. Patients who needed enhanced care differed from those who did not in age, cognitive test scores and Health of the Nation Outcome Scale scores. Logistic regression discriminated risk, with an area under the receiver operating characteristic curve (AUROC) of up to 0.78 after 1 year and 0.74 after 4 years. We were able to confirm the validity of the approach in two trusts that differed widely in the populations they serve. Conclusions It is possible to identify, at the time of diagnosis of dementia, individuals most likely to need enhanced care later in the disease course. This permits the development of targeted clinical interventions for this high-risk group.

psychiatry
Derivation and validation of the Rapid Assessment of Dementia Risk (RADaR) for older adults

Ana W. Capuano,Raj C. Shah,Paul Blanche,Robert S. Wilson,Lisa L. Barnes,David A. Bennett,Zoe Arvanitakis

DOI: https://doi.org/10.1371/journal.pone.0265379

IF: 3.7

2022-03-17

PLoS ONE

Abstract:Background There is no practical dementia risk score in the clinical setting. Objective To derive and validate a score obtained by a rapid and simple assessment, which guides primary care providers in predicting the risk of dementia among older adults. Design A total of 4178 participants from three longitudinal cohorts (mean age at baseline = 76.8 [SD = 7.6] years), without baseline dementia, followed annually for a median of 10 years (IQR: 5 to16 years, Reverse Kaplan-Meier). Participants To derive the score, we used data from 1,780 participants from the Rush Memory and Aging Project (93% White). To validate the score, we used data from 1,299 participants from the Religious Order Study (92% White), and to assess generalizability, 679 participants from the Minority Aging Research Study (100% Black). Measurements Clinician-based dementia diagnosis at any time after baseline and predictive variables associated with dementia risk that can be collected in a primary care setting: demographics, clinical indicators, medical history, memory complaints, cognitive and motor tests, and questions to assess functional disability, depressive symptoms, sleep, social isolation, and genetics (APOE e4 and AD polygenic risk score). Results At baseline, age, memory complaint, the ability to handle finances, the recall of the month, recall of the room, and recall of three words, were associated with the cumulative incidence of dementia, in the derivation cohort. The discrimination of the RADaR (Rapid Risk Assessment of Dementia) was good for the derivation and external-validation cohorts (AUC 3 years = 0.82–0.86), compared to the overall discrimination of age alone (AUC 3 years = 0.73), a major risk factor for dementia. Adding genetic data did not increase discrimination. Limitations Participants were volunteers, may not represent the general population. Conclusions The RADaR, derived from community-dwelling older persons, is a brief and valid tool to predict dementia risk at 3 years in older White and Black persons.

multidisciplinary sciences
Habituation in Limulus abdominal ganglia.

R. Lahue,W. Corning

DOI: https://doi.org/10.2307/1540279

1971-06-01

Abstract:1. Extracellular recordings were made from dorsal root units in the abdominal ganglia of Limulus. These units are activated by tactile stimulation of the gill book covers.2. The response in these units to repeated puffs of air directed on a gill book is a rapid decline in activity. The response "spontaneously recovers" with time when the stimulus is withheld. Stronger stimuli or different stimuli (water drops) produce an immediate recovery of the diminished responsivity; this recovery is similar to "dishabituation" noted in other studies and rules out fatigue as an explanation for the dorsal root response decrement. Sensory fatigue or adaptation are ruled out by the demonstration that repeated puffs of air do not produce any response decrement in the nerves (ventral roots) which carry the afferent tactile information.3. The relationship between the number of ganglia and the acquisition of habituation was examined and no differences were found. However, during retests the Intact and Isolated Ventral Cord p...
ASGARD risk scores for long-term, individualized cardiovascular surveillance of low-risk patients with asymptomatic non-severe aortic valve stenosis: development and internal validation

E Hadziselimovic,A M G Greve,A S Sajadieh,M H O Olsen,Y A K Kesaniemi,C A N Nienaber,S G R Ray,A B R Rosseboe,K W Wachtell,H D Dominguez,N V K Koeber,H G C Carstensen,O W N Nielsen

DOI: https://doi.org/10.1093/eurheartj/ehad655.2449

IF: 39.3

2023-11-01

European Heart Journal

Abstract:Abstract Background Routine echocardiography of asymptomatic patients with non-severe aortic valve stenosis (AS) mainly focuses on the valve condition at 1-2 year intervals but has limited ability to predict the risk of other cardiovascular comorbidities. Thus, there is a compelling need to replace routine echocardiography for low-risk patients with more individualized cardiovascular surveillance for a safe period. Aim First, to develop and validate separate risk stratification models for AS-related events (AVE) and major cardiovascular events (MCE) to identify low-risk AS patients who can safely postpone routine echocardiography replaced by tailored risk stratification and adequate risk factor management. Second, to estimate optimal follow-up intervals according to risk stratification for each outcome. Methods We analyzed serial measurements from 69% of 1579 patients with mild-to-moderate AS who were asymptomatic and event-free one year after inclusion in the randomized, multicenter Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. We developed two ASGARD risk scores using multivariable Cox proportional hazard regression analyses, designed as landmark analyses starting at year-1 and with a clinically relevant 2-year follow-up. The ASGARD scores estimated the risk of AVE (composite of aortic valve replacement or hospitalization with heart failure) and MCE (composite of myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, and all-cause mortality). We estimated the prognostic models with backward elimination, selecting the lowest Akaike information criterion values and p<0.05. There were 7 predictors for AVE and 6 for MCE among current demographic, electrocardiograms, laboratory data, and echocardiographic measures one year earlier (baseline) (Figures 1A, 2A). We defined optimal follow-up for risk score quartiles at rates ≤5% visualized on Kaplan-Meier plots. We assessed model performance in 31% of patients held out for internal validation. Results ASGARD development models for both AVE and MCE risk demonstrated overall consistent predictive performance in the internal validation cohort, as evidenced by c-statistics, calibration-in-the-large, calibration slope, Brier score, and goodness-of-fit (all p>0.05) (Figure 1B-C, 2B-C). ASGARD predicted AVE risk similar to a new Vmax measurement (area under the curve [95% CI], 0.82 [0.78-0.87] vs. 0.85 [0.82-0.89) (Figure 1B), and MCE risk better than Framingham cardiovascular risk score (0.76 [0.70-0.82] vs. 0.68 [0.62-0.75]) (Figure 2B). The one-year event rates were ≤5% for the 2 lowest risk score quartiles (Figure 1D, 2D). Conclusion The ASGARD risk scores show promise for long-term, individualized cardiovascular surveillance of low-risk patients with non-severe AS without unnecessary echocardiography. Further studies are warranted for external model validation, continuous optimization, and exploring the potential for implementation in clinical practice.Figure 1Figure 2

cardiac & cardiovascular systems
Dynamic and transdiagnostic risk calculator based on Natural Language Processing for the prediction of psychosis in secondary mental health care: development and internal-external validation cohort study.

Kamil Krakowski,Dominic Oliver,Maite Arribas,Daniel Stahl,Paolo Fusar-Poli

DOI: https://doi.org/10.1016/j.biopsych.2024.05.022

IF: 12.81

2024-06-09

Biological Psychiatry

Abstract:Background Automatic transdiagnostic risk calculators can improve detection of individuals at risk of psychosis. However, they rely on a single point in time assessment and can be refined with dynamic modelling techniques that account for changes in risk over time. Methods We included n=158,139 patients (n=5,007 events) receiving a first index diagnosis of a non-organic and non-psychotic mental disorder within Electronic Health Records from the SLaM NHS Foundation Trust between 01/01/2008 and 10/08/2021. A dynamic Cox landmark model was developed to estimate the 2-year risk of developing psychosis according to TRIPOD statement. The dynamic model included 24 predictors extracted at nine landmark points (baseline, 0, 6, 12, 24, 30, 36, 42, and 48 months): three demographic, one clinical, and 20 Natural Language Processing (NLP) based symptom and substance use predictors. Performance was compared to a static Cox regression model with all predictors assessed at baseline only, indexed via discrimination (C-index), calibration (calibration plots), and potential clinical utility (decision curves) in internal-external validation. Results The dynamic model improves discrimination performance compared to the static model at baseline (dynamic: C-index=0.9; static: C-index=0.87) to the final landmark point (dynamic: C-index=0.79; static: C-index=0.76). The dynamic model was also significantly better calibrated (calibration slope=0.97-1.1) than the static model at later landmark points (≥24 months). Net benefit was higher in the dynamic compared to the static model at later landmark points (≥24 months). Conclusion These findings suggest that dynamic prediction models can improve detection of individuals at risk for psychosis in secondary mental health care.

neurosciences,psychiatry
Biochemical individuality; a paper chromatographic technique for determining excretion of amino acids in the presence of interfering substances.

H. Berry,L. Cain

1949-11-01

Abstract:
Individualized, cross‐validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms

Emma Borland,Niklas Mattson‐Carlgren,Pontus Tideman,the Alzheimer's Disease Neuroimaging Initiative,Erik Stomrud,Oskar Hansson,Sebastian Palmqvist

DOI: https://doi.org/10.1002/alz.14305

2024-10-18

Alzheimer s & Dementia

Abstract:INTRODUCTION We aimed to develop an algorithm to predict the individualized risk of future dementia using brief cognitive tests suitable for primary care. METHODS We included 612 participants with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study, assessed for at least 4 years or until progression to dementia. A logistic regression model, using cognitive tests as predictors and dementia progression as an outcome, stratified participants into low, intermediate, or high risk. A second model, including 1‐year cognitive test changes, was applied to the intermediate group. The models were replicated in 392 SCD/MCI participants from the BioFINDER‐1 study. RESULTS The best two‐step model for predicting dementia incorporated Trail Making Test B (attention/executive function), Animal Fluency (verbal fluency), Mini‐Mental State Examination (global cognition), and 10‐word list recall (memory). The model's positive predictive value in ADNI was 85.8% and negative predictive value was 92.2% versus 62.5% and 95.6%, respectively, in BioFINDER‐1. DISCUSSION This two‐step model accurately predicts individualized dementia risk. Highlights To our knowledge, this is the first algorithm for predicting all‐cause dementia using a novel two‐step model utilizing brief cognitive tests. Applying a validated model including the Trail Making Test B, Animal Fluency, MMSE, Alzheimer's Disease Assessment Scale delayed, and immediate recall can robustly and accurately categorize individuals into low, intermediate, or high risk of dementia progression and can facilitate clinical decision‐making and personalized patient care. We created an app that is available for research and educational purposes at https://brainapps.shinyapps.io/PredictAllCauseDementia to provide an individualized risk score for dementia progression.

clinical neurology

Tinkering Around Healthcare Infrastructures: Nursing Practices and Junction Work

Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis

A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views

Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Accuracy of MSBase Criteria to Diagnose Secondary Progressive Multiple Sclerosis in Large German Real-World Patient Cohort

Validation of a Set of Clinical Criteria for the Diagnosis of Secondary Progressive Multiple Sclerosis

Development and validation of a clinical prediction tool to estimate survival in community-dwelling adults living with dementia: a protocol

Accurate classification of secondary progression in multiple sclerosis

Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

Recurrent prostate cancer despite undetectable prostate specific antigen.

Identifying individuals at high risk for dementia in primary care: Development and validation of the DemRisk risk prediction model using routinely collected patient data

Development and validation of a dementia risk score in the UK Biobank and Whitehall II cohorts

Predicting patients with dementia most at risk of needing psychiatric in-patient or enhanced community care using routinely collected clinical data: retrospective multi-site cohort study

Derivation and validation of the Rapid Assessment of Dementia Risk (RADaR) for older adults

Habituation in Limulus abdominal ganglia.

ASGARD risk scores for long-term, individualized cardiovascular surveillance of low-risk patients with asymptomatic non-severe aortic valve stenosis: development and internal validation

Dynamic and transdiagnostic risk calculator based on Natural Language Processing for the prediction of psychosis in secondary mental health care: development and internal-external validation cohort study.

Biochemical individuality; a paper chromatographic technique for determining excretion of amino acids in the presence of interfering substances.

Individualized, cross‐validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms